key: cord-0938049-zxv5kmew
authors: Dissanayake, Harsha Anuruddhika; de Silva, Nipun Lakshitha; Sumanatilleke, Manilka; de Silva, Sawanawadu Dilantha Neomal; Gamage, Kavinga Kalhari Kobawaka; Dematapitiya, Chinthana; Kuruppu, Daya Chandrani; Ranasinghe, Priyanga; Pathmanathan, Sivatharshya; Katulanda, Prasad
title: Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis
date: 2021-12-11
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgab892
sha: 0d6c32bdb4028785cd1ff2983a4fc6c6814d4afa
doc_id: 938049
cord_uid: zxv5kmew

PURPOSE: Vitamin D deficiency/insufficiency may increase the susceptibility to COVID-19. We aimed to determine the association between vitamin D deficiency/insufficiency and susceptibility to COVID-19, its severity, mortality and role of vitamin D in its treatment. METHODS: We searched CINHAL, Cochrane library, EMBASE, PubMED, Scopus, and Web of Science up to 30.05.2021 for observational studies on association between vitamin D deficiency/insufficiency and susceptibility to COVID-19, severe disease and death among adults, and, randomized controlled trials (RCTs) comparing vitamin D treatment against standard care or placebo, in improving severity or mortality among adults with COVID-19. Risk of bias was assessed using Newcastle-Ottawa scale for observational studies and AUB-KQ1 Cochrane tool for RCTs. Study-level data were analyzed using RevMan 5.3 and R (v4∙1∙0). Heterogeneity was determined by I (2) and sources were explored through pre-specified sensitivity analyses, subgroup analyses and meta-regressions. RESULTS: Of 1877 search results, 76 studies satisfying eligibility criteria were included. Seventy-two observational studies were included in the meta-analysis (n=1976099). Vitamin D deficiency/insufficiency increased the odds of developing COVID-19 (OR 1∙46, 95% CI 1∙28–1∙65, p<0∙0001, I (2)=92%), severe disease (OR 1∙90, 95% CI 1∙52–2∙38, p<0.0001, I (2)=81%) and death (OR 2∙07, 95% CI 1∙28–3∙35, p=0.003, I (2)=73%). 25-hydroxy vitamin D (25(OH)D) concentration were lower in individuals with COVID-19 compared to controls (mean difference [MD] -3∙85 ng/mL, 95% CI -5∙44,-2∙26, p=<0.0001), in patients with severe COVID-19 compared to controls with non-severe COVID19 (MD -4∙84 ng/mL, 95% CI -7∙32,-2∙35, p=0∙0001) and in non-survivors compared to survivors (MD -4∙80 ng/mL, 95%-CI -7∙89,-1∙71, p=0∙002). The association between vitamin D deficiency/insufficiency and death was insignificant when studies with high risk of bias or studies reporting unadjusted effect estimates were excluded. Risk of bias and heterogeneity were high across all analyses. Discrepancies in timing of vitamin D testing, definitions of severe COVID-19 and vitamin D deficiency/insufficiency partly explained the heterogeneity. Four RCTs were widely heterogeneous precluding meta-analysis. CONCLUSION: Multiple observational studies involving nearly two million adults suggest vitamin D deficiency/insufficiency increases susceptibility to COVID-19 and severe COVID-19, although with a high risk of bias and heterogeneity. Association with mortality was less robust. Heterogeneity in RCTs precluded their meta-analysis.

COVID-19 pandemic remains a global health challenge, claiming over 4 million lives worldwide. 1 Despite vaccine roll-out at scale, it is expected to remain a problem due to inequities in resource allocation and chance of new mutants evading vaccine-mediated protection. Therefore, other treatment and prevention strategies for COVID- 19 have been an area of extensive research.

Vitamin D is implicated in optimum function of the immune system. Its deficiency has been linked to susceptibility to respiratory infections. 2, 3 It is postulated that vitamin D deficiency/insufficiency is also associated with COVID-19. Low cost, wider availability and ease of administration would make it an attractive and practice-changing intervention if proven effective. These hypotheses have been tested in several observational and interventional studies. Despite strong scientific suspicion, those have yielded variable results. Conclusions of meta-analyses summarizing these have also been mixed. [4] [5] [6] [7] [8] [9] [10] [11] [12] Significant but unexplained heterogeneity is common to all analyses. Since the publication of those reports, several more studies have been published. Therefore, we aimed to systematically review the literature and determine:

1.

Does vitamin D deficiency/insufficiency increase the susceptibility to COVID-19 infection, risk of developing severe COVID-19 and risk of death from COVID-19 among adults?

In adults with COVID-19, does treatment with vitamin D compared to standard care/placebo improve clinical outcome?

A c c e p t e d M a n u s c r i p t

We conducted a systematic review and independent meta-analyses for three different outcomes of interest: susceptibility to COVID-19, risk of developing severe COVID-19 and death from COVID-

We searched for observational studies (prospective or retrospective cohort or case-control) in adults (above 18 years) comparing the rates of above outcomes in groups with and without vitamin D deficiency/insufficiency, and, for observational studies comparing 25-hydroxy vitamin D (25(OH)D) concentration in people with or without above outcomes. We also searched for randomized controlled trials comparing vitamin D therapy against placebo/standard care in improving clinical end-points (length of hospital stay, severe COVID-19, death or any combination) when used to treat adults with COVID-19.

We searched CINHAL, Cochrane library, EMBASE, PubMED, Scopus, and Web of Science databases from their inception to 30•05•2021, using keywords "SARS-CoV-2" OR "COVID-19" OR "Coronavirus" OR "Coronavirus disease 2019" OR "new coronavirus infection" OR "novel coronavirus infection" OR "Coronavirus infection" OR "SARS" OR "severe acute respiratory syndrome" / "vitamin D deficiency" OR "vitamin D insufficiency" OR "hypovitaminosis D" / "treatment" / "vitamin D" OR "cholecalciferol" OR "calcidol" OR "alfa-calcidol" OR "calcitriol"

OR "calcifediol" in all fields. The search strategy in full is available in supplementary data file 1, section 1. 13 Articles published in English language, analyzing individual patient-level data were selected. Additional references were identified by manually screening references of the published articles. If abstracts alone were published, we contacted authors to request full-texts. If reported data were inadequate to synthesize effect estimates for the meta-analysis, we contacted authors for additional information. If required data could not be obtained, those studies were excluded from the A c c e p t e d M a n u s c r i p t meta-analysis. The other exclusion criteria were reporting of population level data, not reporting the outcomes of interest or analyses in done in duplicate ( 2 reports based on the same population)

Titles/abstracts, and full-texts were screened by two authors independently (SDNdS and CD).

Conflicts were resolved by a third author (HAD). When abstract / research letter alone was available, the data were included in the meta-analysis. Their impact on the pooled effect estimate were assessed through sensitivity analysis.

We used the following definitions to categorize studies in to subgroups for subgroup analysis and/or meta-regression.

Timing of vitamin D testing: We defined 4 categories of timing of vitamin D testing: "long ago"

(more than 1 year before the outcome), "before COVID-19" (within a year preceding COVID-19), "after COVID-19" and "variable timing" (before, during or after COVID-19).

Cut off for vitamin D testing: We categorized the studies according to 25(OH)D cut-off used in analysis into the following categories: category 1 (studies using a cut-off 10±3 ng/mL), category 2 (studies using a cut-off 20±3 ng/mL) and category 3 (studies using a cut-off 30±3 ng/mL). One study that used a cut-off of 15 ng/mL was included in category 1. These approximations were required because different studies used different cut-points to dichotomize the data: either based on local or regional protocols or based on the distribution of the study cohorts" 25(OH)D distribution. We use the term "vitamin D deficiency/insufficiency" to denote vitamin D insufficiency or deficiency of any severity.

Criteria for severe COVID-19: For subgroup analyses, we classified the severity criteria as follows:

"hospitalization" (when hospitalization defines severe disease), "hypoxia" (when need for oxygen, non-invasive or invasive ventilation, acute respiratory distress syndrome, or a combination of these M a n u s c r i p t define severe COVID-19), "death" (when death defines severe disease) or "composite" (when a composite of hospitalization, hypoxia or death defines severe COVID-19).

Two authors independently extracted data from selected articles (NLdS and KKKG) under the domains: publication details, setting, design, participant selection criteria, characteristic of participants, exposure and outcome assessment, statistical analysis, raw data relevant for metaanalysis and adjusted and/or unadjusted effect estimates (format in Supplementary data file 1 section 2). 14 When two studies reported data from the same dataset, authors of both studies were inquired for clarification and the most updated dataset were included in the analysis.

Statistical analysis was conducted in R (v•4•1•0) and RevMan 5•3. Inverse variance method and random-effects model was used to pool effect estimates because we anticipated significant betweenstudy heterogeneity. We used DerSimonian-Laird method to calculate the heterogeneity variance τ 2 and Knapp-Hartung adjustments 14 to calculate the confidence interval around the pooled effect. Forest plots were used for graphical representation. Statistical assessments were two-tailed and a p-value less than 0•05 was considered significant.

Susceptibility to infection / severe disease / death was reported as odds ratio in most selected studies.

When it was not available, raw data were extracted from the articles to calculate the odds ratios. When adjusted odds ratios were reported (with or without unadjusted odds ratios), those were used for the meta-analysis. All 25(OH)D concentration were converted to ng/mL (1 ng/mL = 2.5 nmol/L) units and mean differences were determined. When median and range or interquartile range of vitamin D were reported, approximate mean and standard deviations were calculated and adopted for the metaanalysis. [15] [16] [17] A c c e p t e d M a n u s c r i p t

Robustness of findings were assessed by sensitivity analysis. Heterogeneity across studies was estimated with I 2 statistic. Source of heterogeneity was explored using subgroup analyses and metaregression.

Elements for sensitivity analyses defined a priori were extreme effect estimates (odds ratios < 0•2 or > 5•0; mean differences greater than the 95% confidence interval limits), extreme sample sizes (<100 or >10000), type of publication (with and without abstract-only publications), risk of bias (with and without publications with high risk of bias), and type of effect estimate (adjusted vs unadjusted). Cut off for definition of vitamin D deficiency/insufficiency, criteria to define severe COVID-19 and geographical territory of the study were the predictor variables defined a priori for meta-regression.

The model fit was assessed by weighted least squares method. Multiple meta-regression models were assessed by forward selection step-wise approach. The predictor sequence was determined by single variable meta-regression analyses. The models were compared using ANOVA likelihood-ratio test and corrected Akaike"s Information Criterion (AICc). Robustness of the models was ascertained by permutation testing.

The risk of bias was assessed using Newcastle and Ottawa scales for cohort and case-control studies and AUB KQ1 Cochrane tool for RCTs. Two authors independently assessed each publication (NLdS, KKKG). Conflicts were resolved by a third author (HAD). Abstracts and research letters were not A c c e p t e d M a n u s c r i p t subjected to risk of bias analysis due to limited availability of data. Impact of publications with high risk of bias was assessed by conducting sensitivity analyses. Publication bias was assessed by Funnel plots and by Egger"s test.

The literature search yielded 1877 records. After excluding duplicates, 1166 titles/abstracts were 

Nineteen studies (1967068 participants) reported odds ratios for the association between vitamin D The mean 25(OH)D concentration in people with COVID-19 infection was lower compared to those without (mean difference -3•85 ng/mL, 95% CI -5•44, -2•26, p = < 0•0001) ( Figure 4 ). Heterogeneity across studies was high (I 2 =97•7%, p<0•0001). Difference remained significant in all sensitivity analyses (supplementary data file 1, section 6). 13 In summary, vitamin D deficiency/insufficiency increased the odds of developing COVID-19.

Patients with COVID-19 had lower 25(OH)D concentration that those without. Wide heterogeneity across studies is partly explained by differences in timing of vitamin D testing, geographical territory of the study, cut-off used to define vitamin D deficiency/insufficiency and risk of bias. Most casecontrol studies assessing the association between vitamin D status and risk of developing COVID-19

had a high risk of bias since exposure status was determined after the onset of outcome.

Thirty-six studies (367852 participants, 32 full-texts) reported on the association between vitamin D In single variable meta-regression models, none of the tested variables (criteria for vitamin D deficiency/insufficiency, criteria for disease severity, geographical region of the study) effectively predicted the effect size. Therefore, we conducted a post-hoc multi-model analysis including the above pre-specified variables and 2 additional variables: adjusted vs non-adjusted effect estimates and risk of bias. Yet no models effectively predicted the effect size (supplementary data file 1, section 7 Heterogeneity across studies was high (I 2 89%, p<0.00001) ( Figure 6 ). The significance in difference remained in sensitivity analyses conducted excluding abstract only publications, studies with high risk of bias and extreme effect size (mean difference greater than the upper limit of 95% confidence interval, ie 8•04 ng/mL).

In summary, vitamin D deficiency/insufficiency increased the odds of developing severe COVID-19. 

Four randomized controlled trials assessed vitamin D therapy in treatment of COVID-19 (Table 2) Previous meta-analyses explored the association between vitamin D deficiency/insufficiency and risk of developing COVID-19 11, 12 , or developing complications of the disease, 5 or both 8,10 while another reported prevalence of vitamin D deficiency/insufficiency among patients with COVID-19 without a comparison group. 94 All included less than 40 studies in meta-analysis. A significant association was shown in some 10,11 but not others. 8 Significant heterogeneity was a common feature, but the sources remained inadequately explained. Three meta-analysis reported therapeutic benefit of vitamin D in patients with COVID-19. 6, 9, 95 This meta-analysis is the most updated and largest in terms of number of studies and participants, in the topic to the best of our knowledge. We explored clinically relevant endpoints: susceptibility to 

Registration This meta-analysis was not registered

This research did not receive any funding A c c e p t e d M a n u s c r i p t M a n u s c r i p t 

Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and metaanalysis of 43 observational studies

Vitamin D deficiency aggravates COVID-19: systematic review and metaanalysis

Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis

Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis. Adv nutr (Bethesda Md, Online)

The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis

The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A

Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis. Front Nutr

Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis

The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis. Front Public Heal

Supplementary material_Vitamin D and COVID-19 systematic review and meta-analysis

Improved tests for a random effects meta-regression with a single covariate

Djulbegovic and IH. Estimating the Mean and Variance from the Median, Range, and the Size of a Sample

Optimally estimating the sample mean from the sample size, median, mid-range and/or mid-quartile range. Optim Estim sample mean from sample size, Median mid-range and/or mid-quartile range

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

The link between vitamin D deficiency and Covid-19 in a large population

AA Wells AM. Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients

The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case-control study of hospitalized patients in Tehran, Iran

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19

Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics with COVID-19 Test Results

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

Does vitamin D serum level affect prognosis of COVID-19 patients?

Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients

Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital

Vitamin D deficiency and outcome of COVID-19 patients

Greater risk of severe COVID-19 in black, asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: Study of 1326 cases from the UK biobank

Low Levels of Vitamin D were Associated with Coagulopathy among Hospitalized Coronavirus Disease-19 (COVID-19) Patient: a Single Centered Study in Indonesia

Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients

Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality

Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System

A notable key for estimating the severity of COVID-19: 25-hydroxyvitamin D status

Retrospective analysis of vitamin D status on ınflammatory markers and course of the disease in patients with COVID-19 infection

Serum Vitamin D levels are associated with increased COVID-19 severity markers and mortality independent of visceral adiposity

Low 25-hydroxyvitamin D levels on admission to the intensive care unit may predispose COVID-19 pneumonia patients to a higher 28-day mortality risk: A pilot study on a greek icu cohort

Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study

Vitamin d deficiency and ards after sars-cov-2 infection

Original publication: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity

Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D

serum 25(oH)D level in patients with CoVID-19

Covid-19 reminds us: Community vitamin d deficiency

The Influence of Vitamin D Status on the Severity of SARS-CoV-2 Respiratory Infection

Low Levels of Vitamin D Are Associated With Markers of Immuno-Inflammatory Response and Clinical Outcome in Covid-19

Influence of vitamin d levels on the clinical course in patients with COVID 19: An argentine pilot and multicenter real-life study

Vitamin D Status as a Potential Modifiable Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

La deficiencia de vitamina D es un factor de riesgo de mortalidad en pacientes con COVID-19 (Deficiency of vitamin D is a risk factor of mortality in patients with COVID-19)

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study

Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease

Effect of a Single High Dose of Vitamin D3on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial

Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study)

Alireza Motamedzadeh, Ehsan Dadgostar, Marzieh Aalinezha DS. The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis

Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis

Vitamin D in acute stress and critical illness

Vitamin D levels associate with blood glucose and BMI in COVID-19 patients predicting disease severity

M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t